在此次高质量数据集建设先行先试工作单位中，涉及金融服务的有证通股份有限公司申报的《资本市场 融资企业高质量数据集建设》，以及恒生电子（600570）股份有限公司申报的《面向金融行业大模型的 多模态高质量数据集建设》，这两项申报不仅代表了资本市场对数据资源的深度探索，更揭示了数据要 素驱动金融业态变革的重要价值。 高质量数据集通过整合企业研发投入、专利数据、供应链关系等多维度信息，构建动态化企业画像，能 够降低信息不对称问题，投资者和金融机构能够精准识别企业技术领先性与商业化潜力，进而提升对很 多轻资产、高成长性企业的风险评估能力。 高质量数据集是人工智能时代的"战略资源"，尤其在金融、能源、交通等关键领域，数据集建设与治理 是保障产业链供应链韧性的重要基石。国家数据局在今年4月份发布的《全国数据资源调查报告(2024 年)》显示，2024年我国高质量数据集数量同比增长27.4%，有力支撑人工智能训练和应用。 中关村物联网产业联盟副秘书长袁帅对记者分析，数据质量是人工智能从"可用"向"好用"跨越的关键瓶 颈，高质量数据集建设先行先试工作通过"场景驱动+示范先行"策略，推动跨部门、跨行业数据协同， 通过政策引导与 ...

Core Viewpoint - Guangzhou Kingmed Diagnostics Group Co., Ltd. reported a net loss of 85 million yuan in the first half of 2025, despite achieving an operating income of 2.997 billion yuan and a significant increase in operating cash flow by 920% year-on-year to 350 million yuan [1] Group 1: Financial Performance - The company experienced a net profit loss of 85 million yuan due to credit impairment losses of 272 million yuan [1] - Operating cash flow improved significantly, reaching 350 million yuan, marking a year-on-year growth of 920% [1] Group 2: Market Position and Collaborations - The revenue proportion from tertiary hospitals increased to 51.18%, up by 5.43 percentage points year-on-year [2] - Kingmed has established partnerships with over 210 hospitals, universities, and research institutions, including collaborations with top-tier hospitals for multi-center research and laboratory construction [2] Group 3: AI and Technological Advancements - The company launched the "AI IN ALL" initiative, developing 55 intelligent applications to enhance business processes [3] - AI-assisted diagnostics were utilized 2.2 million times in laboratories, improving efficiency, particularly with a 70% increase in report issuance efficiency for tumor molecular reporting systems [3] Group 4: Data and Compliance Initiatives - Kingmed accumulated over 3 billion medical testing data and successfully launched 21 data products on data exchanges in major cities [4] - The company was selected as the only medical institution in the first batch of national trusted data space innovation development pilots, facilitating compliant data circulation and exploring new data flow possibilities [4]

Core Viewpoint - The company reported a total revenue of 2.997 billion yuan for the first half of 2025, with a net profit attributable to shareholders of -85 million yuan, while operating cash flow improved significantly to 350 million yuan, a year-on-year increase of 920% [1] Group 1: Financial Performance - Total revenue for the first half of 2025 was 2.997 billion yuan, with a credit impairment loss of 272 million yuan, resulting in a net profit of -85 million yuan [1] - Operating cash flow reached 350 million yuan, reflecting a year-on-year growth of 920% [1] Group 2: Industry Context - The medical testing industry is undergoing a deep adjustment period driven by multiple factors including healthcare reform, technological revolution, ecological restructuring, and data application [1] Group 3: Competitive Advantages - The company has established a differentiated competitive advantage through product portfolio optimization, continuous innovation, and the development of regional testing center solutions [1] - The company has also built a cost competitive advantage through lean operations and intelligent empowerment [1] Group 4: Product Growth - The company launched several high-cost performance products in oncology, infectious diseases, and Alzheimer's early screening, achieving significant revenue growth: 85% for the "惠民3000" series, 49.99% for the Meta series, and 68.43% for the Alzheimer's screening series [1] - The revenue proportion from tertiary hospitals increased to 51.18%, up by 5.43 percentage points year-on-year [1] Group 5: Collaborative Efforts - The company has established partnerships with over 210 hospitals, universities, and research institutions, including collaborations with top-tier hospitals for multi-center research and joint laboratory construction [2] Group 6: AI Integration - The company launched the "AI IN ALL" initiative, developing 55 intelligent applications that enhance business process automation, with AI-assisted diagnostics being utilized 2.2 million times annually [3] - The "小域医" application has over 60,000 active doctors monthly and has processed over 3.6 million report interpretations [3] Group 7: Data Utilization - The company has accumulated over 3 billion medical testing data entries and successfully launched 21 data products on various data exchanges [4] - The company was selected as a pilot for the national trusted data space innovation development, being the only medical institution included [5]

Core Insights - The core viewpoint of the articles highlights the performance and strategic initiatives of Kingmed Diagnostics (金域医学) in the medical testing industry, particularly in the context of its financial results and innovative approaches to enhance operational efficiency and market competitiveness. Financial Performance - In the first half of 2025, Kingmed Diagnostics reported total revenue of 2.997 billion yuan, with a net profit attributable to shareholders of -85 million yuan due to credit impairment losses of 272 million yuan. However, the operating cash flow improved significantly, reaching 350 million yuan, a year-on-year increase of 920% [1]. Industry Trends - The medical testing industry is undergoing a deep adjustment period driven by multiple factors, including healthcare reform, technological advancements, ecological restructuring, and data application [1]. Product and Service Innovation - Kingmed Diagnostics launched several high-cost performance products in oncology, infectious diseases, and neurology, achieving significant revenue growth: the "惠民3000" series for tumors grew by 85%, the Meta series for infectious diseases by 49.99%, and the early screening series for Alzheimer's disease by 68.43%. The revenue from tertiary hospitals increased to 51.18%, up by 5.43 percentage points year-on-year [2]. Collaborative Efforts - The company has established partnerships with over 210 hospitals, universities, and research institutions, collaborating on multi-center research and joint laboratory construction with top-tier hospitals [2]. AI Integration - Kingmed Diagnostics has initiated the "AI IN ALL" program, developing 55 intelligent applications to enhance business processes. AI-assisted diagnostics were utilized 2.2 million times in a year, improving laboratory efficiency significantly, with a 70% increase in report issuance efficiency for the tumor molecular reporting system [3]. Data-Driven Growth - The company has accumulated over 3 billion medical testing data samples and successfully launched 21 data products on data exchanges in major cities. It was selected as a pilot for the national trusted data space innovation development, being the only medical institution to achieve this [4]. Commercial Model Exploration - Kingmed Diagnostics has developed a compliant commercial model for the circulation of medical testing data, collaborating on 20 projects with various entities, including public health departments and pharmaceutical companies. The company is actively involved in major public health initiatives, including infectious disease monitoring and emergency response [5].